WO2007072529A2 - Process for the synthesis of intermediates for the preparation of astaxanthin - Google Patents
Process for the synthesis of intermediates for the preparation of astaxanthin Download PDFInfo
- Publication number
- WO2007072529A2 WO2007072529A2 PCT/IT2006/000835 IT2006000835W WO2007072529A2 WO 2007072529 A2 WO2007072529 A2 WO 2007072529A2 IT 2006000835 W IT2006000835 W IT 2006000835W WO 2007072529 A2 WO2007072529 A2 WO 2007072529A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ionone
- oxo
- process according
- acid
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 69
- 230000008569 process Effects 0.000 title claims abstract description 60
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 26
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 26
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 26
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 26
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000543 intermediate Substances 0.000 title abstract description 21
- 230000015572 biosynthetic process Effects 0.000 title abstract description 17
- 238000003786 synthesis reaction Methods 0.000 title abstract description 17
- OBHGOXFSRVNKBS-AATRIKPKSA-N 2,4,4-trimethyl-3-[(e)-3-oxobut-1-enyl]cyclohex-2-en-1-one Chemical compound CC(=O)\C=C\C1=C(C)C(=O)CCC1(C)C OBHGOXFSRVNKBS-AATRIKPKSA-N 0.000 claims abstract description 54
- OBHGOXFSRVNKBS-UHFFFAOYSA-N 4-oxo-beta-ionone Natural products CC(=O)C=CC1=C(C)C(=O)CCC1(C)C OBHGOXFSRVNKBS-UHFFFAOYSA-N 0.000 claims abstract description 53
- PSQYTAPXSHCGMF-BQYQJAHWSA-N β-ionone Chemical compound CC(=O)\C=C\C1=C(C)CCCC1(C)C PSQYTAPXSHCGMF-BQYQJAHWSA-N 0.000 claims abstract description 50
- 150000003839 salts Chemical class 0.000 claims abstract description 38
- SFEOKXHPFMOVRM-UHFFFAOYSA-N (+)-(S)-gamma-ionone Natural products CC(=O)C=CC1C(=C)CCCC1(C)C SFEOKXHPFMOVRM-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 15
- 230000003647 oxidation Effects 0.000 claims abstract description 12
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Chemical class [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 claims abstract description 10
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000011630 iodine Substances 0.000 claims abstract description 8
- 238000002425 crystallisation Methods 0.000 claims abstract description 7
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000004965 peroxy acids Chemical class 0.000 claims abstract description 5
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 80
- 239000000243 solution Substances 0.000 claims description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- 238000006243 chemical reaction Methods 0.000 claims description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 34
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- -1 alkaline earth metal bromate Chemical class 0.000 claims description 22
- 150000002148 esters Chemical class 0.000 claims description 19
- 239000011541 reaction mixture Substances 0.000 claims description 19
- 239000003960 organic solvent Substances 0.000 claims description 16
- 239000005977 Ethylene Substances 0.000 claims description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 239000002253 acid Chemical class 0.000 claims description 14
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical group C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims description 12
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 claims description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical group [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical group 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 claims description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000007800 oxidant agent Substances 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 claims description 6
- XUXNAKZDHHEHPC-UHFFFAOYSA-M sodium bromate Chemical compound [Na+].[O-]Br(=O)=O XUXNAKZDHHEHPC-UHFFFAOYSA-M 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003377 acid catalyst Substances 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 239000012024 dehydrating agents Substances 0.000 claims description 5
- 230000001590 oxidative effect Effects 0.000 claims description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 claims description 4
- 229910001619 alkaline earth metal iodide Inorganic materials 0.000 claims description 4
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 claims description 4
- 229910001511 metal iodide Inorganic materials 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000002524 organometallic group Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 235000009518 sodium iodide Nutrition 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 239000001117 sulphuric acid Substances 0.000 claims description 4
- 235000011149 sulphuric acid Nutrition 0.000 claims description 4
- 150000003509 tertiary alcohols Chemical class 0.000 claims description 4
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 claims description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 3
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical group ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 claims description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 3
- 239000012736 aqueous medium Substances 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- JOPOVCBBYLSVDA-UHFFFAOYSA-N chromium(6+) Chemical class [Cr+6] JOPOVCBBYLSVDA-UHFFFAOYSA-N 0.000 claims description 3
- 229940043279 diisopropylamine Drugs 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 150000002978 peroxides Chemical class 0.000 claims description 3
- WCLKSQYCWXZMGX-UHFFFAOYSA-N 1,2,3,4-tetrabromo-5,6-dimethoxybenzene Chemical compound COC1=C(Br)C(Br)=C(Br)C(Br)=C1OC WCLKSQYCWXZMGX-UHFFFAOYSA-N 0.000 claims description 2
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- XWNSFEAWWGGSKJ-UHFFFAOYSA-N 4-acetyl-4-methylheptanedinitrile Chemical group N#CCCC(C)(C(=O)C)CCC#N XWNSFEAWWGGSKJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004154 Calcium bromate Substances 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000004153 Potassium bromate Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 229910001616 alkaline earth metal bromide Inorganic materials 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 235000019397 calcium bromate Nutrition 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 2
- LBCCRLLCAUOTJN-UHFFFAOYSA-L dipotassium;2-oxidooxycarbonylbenzoate Chemical compound [K+].[K+].[O-]OC(=O)C1=CC=CC=C1C([O-])=O LBCCRLLCAUOTJN-UHFFFAOYSA-L 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 claims description 2
- 229910001509 metal bromide Inorganic materials 0.000 claims description 2
- NSNPSJGHTQIXDO-UHFFFAOYSA-N naphthalene-1-carbonyl chloride Chemical group C1=CC=C2C(C(=O)Cl)=CC=CC2=C1 NSNPSJGHTQIXDO-UHFFFAOYSA-N 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 239000003880 polar aprotic solvent Substances 0.000 claims description 2
- 235000019396 potassium bromate Nutrition 0.000 claims description 2
- 229940094037 potassium bromate Drugs 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims 5
- 239000011260 aqueous acid Substances 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 239000007787 solid Substances 0.000 abstract description 12
- 150000007860 aryl ester derivatives Chemical class 0.000 abstract description 9
- 238000007239 Wittig reaction Methods 0.000 abstract description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000002994 raw material Substances 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- HJOVHMDZYOCNQW-UHFFFAOYSA-N isophorone Chemical compound CC1=CC(=O)CC(C)(C)C1 HJOVHMDZYOCNQW-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 4
- MWUSAETYTBNPDG-UHFFFAOYSA-N (4-chlorobenzoyl) 4-chlorobenzoate Chemical compound C1=CC(Cl)=CC=C1C(=O)OC(=O)C1=CC=C(Cl)C=C1 MWUSAETYTBNPDG-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000746 allylic group Chemical group 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- NQUIJCWGBOFEPG-UHFFFAOYSA-N 1,2-bis(2-hydroxyethylsulfanyl)ethanol Chemical compound OCCSCC(O)SCCO NQUIJCWGBOFEPG-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- NZCKTGCKFJDGFD-UHFFFAOYSA-N 2-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Br NZCKTGCKFJDGFD-UHFFFAOYSA-N 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- IJMNXZHEDVWINS-AATRIKPKSA-N CC(C)(CC1O)C(/C=C/C(C)=O)=C(C)C1=O Chemical compound CC(C)(CC1O)C(/C=C/C(C)=O)=C(C)C1=O IJMNXZHEDVWINS-AATRIKPKSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 241000277269 Oncorhynchus masou Species 0.000 description 1
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 238000006465 cis-Wittig olefination reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000004967 organic peroxy acids Chemical class 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- JXHZRQHZVYDRGX-UHFFFAOYSA-M sodium;hydrogen sulfate;hydrate Chemical compound [OH-].[Na+].OS(O)(=O)=O JXHZRQHZVYDRGX-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000000207 volumetry Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/04—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
- C07C403/08—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
- C07C403/16—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms not being part of —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5428—Acyclic unsaturated phosphonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Definitions
- the present invention relates to a process for the preparation of intermediates useful in the synthesis of Astaxanthin, in particular Ci 5 -Wittig salts, but also 4-oxo- ⁇ -ionones, 3-hydroxy-4-oxo- ⁇ -ionones and the aryl esters thereof.
- Astaxanthin in particular Ci 5 -Wittig salts
- 4-oxo- ⁇ -ionones 3-hydroxy-4-oxo- ⁇ -ionones and the aryl esters thereof.
- Astaxanthin is a carotenoid found widely throughout nature (for example it is present as a pigment in numerous crustaceans) and is of significant commercial interest as a food additive; it is mainly used as a natural food-colouring for fish, in order to give the flesh a colour similar to that of salmon (for example salmon trout) . Even though initially, Astaxanthin was extracted from crushed crustacean shells, given the rather large quantities required on the global market, which is in continual expansion, it is currently more often produced by chemical synthesis.
- Cio-dialdehyde intermediate 3_ may be prepared by following the indications given in the UK patent GB 768172.
- Ci 5 -Wittig salt intermediate 2 is rather more difficult .
- the current industrial synthetic processes for this intermediate start from a cheap and commercially available raw material known as isophorone, which has the following formula:
- ⁇ -ionone 4 is oxidised to 4-oxo- ⁇ -ionone j>, then transformed into the corresponding monoketal £, then oxidised in the presence of excess lead tetra-acetate in toluene to give 3-acetoxy-4-oxo- ⁇ -ionone monoketal "7 and then finally de-protected to give 3-acetoxy-4-oxo- ⁇ -ionone £ with an overall yield of 58% from j>.
- the key reaction is the transformation of 3-acetoy-4-oxo- ⁇ -ionone £ into the intermediate £, which is then converted to the Wittig salt £ by hydrolysis of the ester, rearrangement of the tertiary alcohol Ij) to the corresponding allyl bromide 11 and finally reaction with triphenylphosphine .
- US patent US 4209450 claims a process in which ⁇ -ionone 4_ is oxidised directly to give 4-oxo- ⁇ - ionone £> by means of a biphasic chloroform/aqueous sulphuric acid system, using as an oxidant a large excess of sodium chlorate, in the presence of catalytic quantities of iodine or sodium iodide: following reaction for 24 hours at 45°C, the product is isolated initially as a crude oil with a yield of 56% and subsequently purified by high vacuum fractional distillation to give 4-oxo- ⁇ -ionone EJ with a final yield of 40%.
- repetition of the procedure reported in the aforementioned patent has not lead to the attainment of significant quantities of product (see example 1) .
- the present invention relates to a process for the preparation of astaxanthin wherein the distinguishing feature is the process for the preparation of a C 15 - Wittig salt 2 starting from a ⁇ -ionone £, through the intermediates 3-hydroxy-4-oxo- ⁇ -ionone 12 and the aryl esters thereof.
- Said process is characterised by the use of cheap and non-toxic raw materials, it is simple and easily industrialisable and gives good molar yields.
- the aryl esters of 3-hydroxy-4- oxo- ⁇ -ionone "L2.
- the ⁇ -ionone A is oxidised to 4-oxo- ⁇ -ionone !5 by means of a particularly advantageous method.
- the process comprises an oxidation step of the ⁇ -ionone which allows it to be obtained with high yield.
- the process comprises ten synthetic steps, but with the isolation of just two solid intermediate, namely the 4-oxo- ⁇ -ionone E> and the aryl ester of the 3- hydroxy-4-oxo- ⁇ -ionone ⁇ £5 (see scheme 3) .
- the Ci 5 - Wittig salt 2_ is then used for the synthesis of Astaxanthin 1, according to the synthetic scheme known in the art, i.e. through l a Wittig condensation reaction with a Ci O -dialdehyde 3_ (see schema 1) .
- the bromate used is preferably selected from sodium bromate, potassium bromate and calcium bromate, more preferably sodium bromate.
- the quantity i of bromate used preferably be between 0.5 and 1.5 equivalents, more preferably between 0.9 and 1.1 equivalents.
- the iodide used is preferably selected from sodium iodide and potassium iodide, and the quantity thereof is preferably between 0.05 and 1.0 equivalents, more preferably between 0.05 and 0.2 equivalents.
- the organic solvent is selected from aliphatic and aromatic hydrocarbons, ethers and esters, chlorinated hydrocarbons, alcohols and polar aprotic solvents, preferably from hexane, cyclohexane, toluene, t-butyl methyl ether, THF, ethyl acetate, isopropyl acetate, methylene chloride, chloroform, chlorobenzene, dimethyl sulphoxide and methanol, more preferably methylene chloride.
- the reaction is carried out at a temperature between 0 and 100 0 C, preferably between 20 and 70 0 C, more preferably between 30 and 40 0 C.
- the reaction time is generally between 1 and 8 hours.
- the acidic aqueous medium is constituted by dilute aqueous solutions of mineral or organic acids, acid salts or a mixture of an acid and its corresponding salt so as to form a buffer solution.
- the acid is an inorganic acid, preferably selected from sulphuric acid, hydrochloric acid, phosphoric acid, sodium bisulphate, more preferably sodium bisulphate, or an organic acid, preferably selected from acetic acid, formic acid and citric acid.
- the quantity of acid is preferably between 0.1 and 1.0 equivalents, more preferably between 0.1 and 0.4 equivalents. It has been observed experimentally that the oxidation reaction is more selective and clean when using aqueous solutions of relatively weak mineral acids, just like sodium bisulphate, where the system is buffered to pH 2-3 during the course of the entire reaction.
- the work-up comprises washing the aqueous phase with an aqueous solution of sodium bisulphite and sodium hydroxide, so as to reduce the iodine once more to iodide and break down any excess oxidant still present.
- the 4-oxo- ⁇ -ionone 5 is finally isolated by separation of the aqueous phase and evaporation of the organic solvent, and obtained with an overall yield between 85% and 95% and purity generally in excess of 90%.
- the product may be purified by crystallisation from a suitable apolar organic solvent, preferably selected from pentane, hexane, heptane, or mixtures of the isomers thereof, more preferably a heptane isomer mixture, and obtained with a yield between 70% and 80% with respect to ⁇ -ionone 4 ⁇ and purity in excess of 97%.
- a suitable apolar organic solvent preferably selected from pentane, hexane, heptane, or mixtures of the isomers thereof, more preferably a heptane isomer mixture
- 4-oxo- ⁇ -ionone monoketal j> is prepared by reacting 4- oxo- ⁇ -ionone !5 with ethylene glycol in the presence of an acid catalyst and a dehydrating agent.
- the acid catalyst is an inorganic or organic acid, preferably selected from sulphuric, hydrochloric, hydrobromic, methanesulphonic and p-toluenesulphonic acid, more preferably p-toluenesulphonic acid.
- the dehydrating agent is preferably an orthoformate or an orthoacetate, more preferably ;trimethyl orthoformate.
- the reaction for the formation of trimethylsilyloxy- ⁇ - ionone 9-ethylene ketal 13_ may be conveniently carried out using a silanising agent preferably selected from chlorotrimethylsilane, bromotrimethylsilane, iodotrimethylsilane and hexamethyldisilazane, more preferably chlorotrimethylsilane, and an organic and organometallic base, preferably selected from triethylamine, diisopropylethylamine, lithium diisopropylamide, lithium bis (trimethylsilyl) amide, more preferably lithium diisopropylamide.
- the lithium diisopropylamide may be prepared conveniently and economically in situ by reacting d ⁇ sopropylamine and n-butyl lithium.
- the oxidation reaction to 3-hydroxy-4-oxo- ⁇ -ionone 12 ⁇ is carried out using a peracid, preferably selected from peracetic acid, m-chloroperbenzoic acid, potassium monoperoxyphthalate, more preferably peracetic acid, or a peroxide or a hydroperoxide.
- a peracid preferably selected from peracetic acid, m-chloroperbenzoic acid, potassium monoperoxyphthalate, more preferably peracetic acid, or a peroxide or a hydroperoxide.
- the solution of peracetic acid in acetic acid is a commercially available and very economical substance.
- the reaction may be conveniently carried out in an organic solvent that is immiscible with water, preferably selected from aliphatic and aromatic hydrocarbons and chlorinated hydrocarbons, more preferably selected from toluene, ' xylene, methylene chloride, chloroform, even more preferably in toluene.
- the intermediate 3-hydroxy-4-oxo- ⁇ -ionone 1£ is obtained after evaporation of the solvent as a crude oil with an overall 4-oxo- ⁇ -ionone. !> yield of 90-100% and purity of 65-75% (by HPLC) , corresponding to a molar weighted yield (HPLC wt %) of 60-65%.
- the intermediate may be purified by high vacuum distillation, but the purity of the crude product is sufficient for its use in the synthesis of the ester derivatives thereof.
- the aforementioned oxidation method allows the attainment of 3-hydroxy-4-oxo- ⁇ -ionone jL2 by means of a process that is significantly improved with respect to that described in HeIv. Chim. Acta.
- Ar is an optionally substituted aryl or heteroaryl group
- Ar is an optionally substituted aryl or heteroaryl group
- Ar is a phenyl group, optionally mono- or polysubstituted with groups preferably selected from alkoxyl, halogen, nitro, cyano and methyl, or a polyaryl group, preferably naphthyl. More preferably
- Ar is a phenyl group, monosubstituted with a halogen or nitro, even more preferably with a chlorine atom.
- Particularly preferred compounds include 3- (4- chlorobenzoyloxy) -4-oxo- ⁇ -ionone of formula 3 ⁇ and 3-
- aryl esters may be synthesised starting from 3- hydroxy-4-oxo- ⁇ -ionone 3L ⁇ , using compounds of formula ArCOX, wherein Ar has the same meaning as above and X is selected from a halogen and RiCOO-, wherein Ri is an alkyl or aryl group, optionally substituted with a substituent that is the identical to or different from Ar.
- acyl halides are used, wherein X is a halogen, in that it is more reactive and more economical than the corresponding anhydrides of formula (ArCO) 2 O or mixed anhydrides.
- ArCO-O- CORi wherein Ri is different from Ar, but sterically hindered.
- a base is used as a hydrohalo acid acceptor which develops, preferably selected from a tertiary amine, for example pyridine or triethylamine, and an inorganic base in aqueous solution, thus operating under Schotten-Baumann conditions.
- the synthesis is conveniently carried out starting from a solution of 3-hydroxy-4-oxo- ⁇ -ionone V ⁇ in a suitable inert organic solvent, such as for example toluene, containing a stoichiometric quantity of triethylamine and a catalytic quantity of 4-dimethylaminopyridine to accelerate the reaction.
- the product may be isolated with good yield and chemical purity by crystallisation from common organic solvents, preferably from alcoholic solvents, more preferably from methanol, ethanol and isopropanol.
- 3- (4-chlorobenzoyloxy) -4-oxo- ⁇ -ionone IS ⁇ is a solid, relatively high-melting product (m.p. 128-132°C) , that can be easily synthesised starting from crude 3- hydroxy-4-oxo- ⁇ -ionone 1£ and 4-chlorobenzoyl chloride, a cheap raw material that is easily available commercially.
- the product is easily- crystallised from methanol and obtained with an overall 4-oxo- ⁇ -ionone IS molar yield of 45-55% and purity generally in excess of 98% (by HPLC).
- 3- (4- chlorobenzoyloxy) -4-oxo- ⁇ -ionone lj ⁇ has been shown to be a particularly useful intermediate for the preparation of the Cis-Wittig salt 2_ and hence Astaxanthin 1.
- 3- (4-chlorobenzoyloxy) -4-oxo- ⁇ -ionone 16 other aryl esters of formula 15 useful for the synthesis of Astaxanthin 1 have, been synthesised: benzoyl, 2-bromobenzoyl, 2-nitrobenzoyl, 3- chlorobenzoyl, 3,4-dichlorobenzoyl, 2-naphthoyl and 1- naphthoyl esters.
- esters of 3-hydroxy-4-oxo- ⁇ -ionone 12 ⁇ of general formula IS 1 are then converted in five steps to the Ci 5 - Wittig salt £ and, thereafter, to Astaxanthin 1 according to published procedures. Indeed, such esters are alkylated by reaction with a Grignard or lithium salt of acetylene in order to obtain the corresponding tertiary alcohol, which is selectively reduced by hydrogenation catalysed by Pd/CaCO 3
- the synthetic process forming the subject of the present invention allows the attainment of the Ci 5 -Wittig salt :2 by using a multi- step synthetic pathway, but consisting of the isolation of just two solid intermediates, namely the 4-oxo- ⁇ -ionone 5 and the ester of 3-hydroxy-4 ⁇ oxo- ⁇ - ionone 1J5.
- the process is likewise characterised by good overall molar yield, by the use of raw materials that are easily obtainable in industrial quantities, and are cheap and non-toxic, by limited environmental impact, so that all the waste products obtained may be disposed of by means of standard incineration plants or biological treatment, and by no means least, simple execution and correct volumetry; all these aspects making the process industrially applicable for the production of Astaxanthin.
- Example 1 (comparative) : 4-oxo- ⁇ -ionone 5
- a round-bottomed flask under an atmosphere of nitrogen, is loaded with 4.8 g of ⁇ - ionone (25 mmol) and 125 mL of chloroform, then 13.3 g of sodium chlorate (125 mmol, 5 eq.) and 0.56 g of sodium iodide (3.7 mmol) dissolved in 50 mL of water are added.
- the solution is acidified with 55 ⁇ L of concentrated sulphuric acid.
- the reaction mixture is heated at 45°C for 24 hours, and the progress of the reaction monitored by GC/HPLC. 2 hours after addition, there are no traces of product in the reaction mixture, and after 24 hours, there is only 6.8%.
- the reaction mix is stirred at 35-40 0 C for 4 hours and the progress of the reaction monitored by GC/HPLC.
- the system is cooled to 25 0 C, the acidic aqueous phase separated and the organic phase treated with a solution containing 31 g of sodium hydroxide in 200 mL of water, then with a solution of 15.6 g of sodium hydroxide in 100. mL of water, then with a solution containing 15.0 mL of acetic acid and 1.5 g of sodium bisulphite in 100 mL of water and finally with 100 mL of water.
- the organic phase is treated with 10 g of acticarbone, filtered, and then concentrated to a residue under vacuum.
- Example 3 4-oxo- ⁇ -ionone 9-ethylene ketal 6
- Into a suitable reactor under ⁇ nitrogen is loaded 80.5 g of 4-oxo- ⁇ -ionone (390 mmol) , 45 mL of methylene chloride and 161 mL of ethylene glycol (2.88 mol) .
- the suspension is stirred at RT for 30 ', then 0.74 g of p- toluenesulphonic acid (3.90 mmol) added.
- a solution constituted by 50.5 mL of trimethyl orthoformate (460 mmol) and 0.105 mL of pyridine (1.3 mmol) is added dropwise at 20-25 0 C over a period of 30-40'.
- the reaction mixture Upon completion of the reaction (GC) the reaction mixture is poured into a mixture constituted by 9.65 g of sodium carbonate dissolved in 80 mL of water and 80 mL of heptane isomer mixture. The phases are separated and the aqueous phase extracted twice with 80 mL of heptane and the organic phases washed twice with 80 mL of water. The organic phase is cooled to 10 0 C and treated with a solution of 68 mL of methanol, 130 mL of water with 11 mL of glacial acetic acid, while the temperature is maintained at 10 0 C. After 7 hours, GC analysis shows the quantity of 4-oxo- ⁇ -ionone 9- ethylene ketal present to be 92-93%.
- reaction- mixture is stirred for at least 30' under nitrogen, then the solvent is evaporated under vacuum to leave a dense residue, which is then diluted with 160 mL of toluene; the inorganic salts present are filtered and washed with toluene.
- the solution containing crude 4- trimethylsilyloxy- ⁇ -ionone 9-ethylene ketal is stored under nitrogen and used directly in the following step.
- Example 6 3- (4-chlorobenzyloxy) -4-oxo- ⁇ -ionone 16
- the toluene solution of 3- hydroxy-4-oxo- ⁇ -ionone prepared according to example 5 51.5 mL of triethylamine and 0.80 g of 4- dimethylaminopyridine; 41.5 mL of p-chlorobenzoyl chloride is added dropwise at 20-25° over the course of one hour and the reaction mix stirred for 3-4 hours.
- 80 mL of water are added and the mixture heated at 4O 0 C for 30 1 .
- the p-chlorobenzoic anhydride by-product is eliminated by filtration while hot.
- the organic phase is separated and the aqueous phase subsequently extracted with 60 mL of toluene.
- the combined organic phases are concentrated to residue under vacuum, taken up with 135 mL of methanol and the solvent evaporated once more under vacuum.
- the solid residue is then taken up with 400 mL of methanol and 1 mL of triethylamine; the suspension is then refluxed and stirred so as to give a solution which is gradually cooled to O 0 C, thus achieving the precipitation of the product .
- the organic ' phase is separated and the aqueous phase extracted twice with 235 mL of heptane and the organic phases washed twice with 235 mL of water.
- the organic phase is cooled to 10 0 C and treated with a solution of 200 mL of methanol, 375 mL of water with 32.5 mL of glacial acetic acid (567 mmol) , while the temperature is maintained at 10 0 C.
- the 4-oxo- ⁇ -ionone 9- ethylene ketal S reaches a quantity in excess of 90% (as judged by GC) .
- the mixture is poured into a solution of 74.7 g of sodium carbonate in 655 mL of water, the phases are separated and the organic phase treated with 23.4 g of anhydrous sodium sulphate and 23.5 g of acticarbone; the suspension is stirred at 20-25° C for 30' and then filtered.
- heptane solution which is added under nitrogen to a solution of lithium diisopropylamide, previously prepared by treating 192 mL of diisopropylamine (1.362 mol) in 280 mL of tetrahydrofuran at 20°C with a solution of 480 mL of 25% n-butyl lithium in heptane (1.339 mol) .
- the resulting solution is stirred for 45 ' at 20°C, then 177 mL of chlorotrimethylsilane (1.170 mol) added dropwise at 20-25°C over 40'.
- reaction mix is stirred for 30', then the solvent evaporated under vacuum to a dense residue, which is then diluted with 460 mL of toluene; the inorganic salts present are filtered and washed with 180 mL of toluene.
- the resulting solution is transferred under an atmosphere of nitrogen into a dropping funnel and then added, over the course of an hour, to a mixture thermostated at -15°C consisting of 310 mL of peracetic acid in 32% acetic acid (1.475 mol) and 160 mL of toluene.
- 12 mL of 32% hydrochloric acid in 235 mL of water are added.
- the reaction mix is stirred for 1.5 hours, then, upon completion of the reaction (as judged by HPLC analysis) neutralised with approx. 320 mL of 30% sodium hydroxide.
- the organic phase is separated and the aqueous phase is extracted with 175 mL of toluene; the combined organic phases are washed with a 235 mL solution containing 4.6 g of sodium bisulphite in water (45 mmol) .
- the organic phase is concentrated to an oily residue, to give 135 g of crude 3-hydroxy-4-oxo- ⁇ -ionone (53% with respect to 4-oxo- ⁇ -ionone) with a purity of 65% (as judged by HPLC) , which is then used crude directly in the subsequent esterification reactions.
- Example 8 3- (1-naphthoyloxy) -4-oxo- ⁇ -ionone 17
- a suitable reaction vessel under nitrogen are loaded 4.0 g of 3-hydroxy-4-oxo- ⁇ -ionone prepared in example 8 (18 mmol theoretical) dissolved in 14 mL of toluene, 2.4 mL of triethylamine (17.2 mmol) and 0.05 g of 4-dimethylaminopyridine; 2.34 mL of 1-naphthoyl chloride (20.3 mmol) dissolved in 5 mL of methylene chloride is added dropwise at 20-25° over 30' and the mixture stirred at 20-25°C for 3-4 hours.
- Example 10 [5- (4-hydroxy-2, 6, ⁇ .-trimethyl-3-oxo- 1-cyclohexen-l-yl) -3-methyl-2, 4- pentadienyl] triphenylphosphonium bromide "Ci 5 -Wittig salt" 2
- a suitable reaction vessel under nitrogen, is loaded 35 mL of 5% ethinylmagnesium chloride (17.5 iranol) in toluene and THF (Chemetall) , the mixture is cooled to -10 0 C and a solution containing 5.0 g of 3- (4-chlorobenzyloxy) -4-oxo- ⁇ -ionone (13.8 mmol) in v.
- the mixture is hydrogenated at 1 bar at RT.
- the catalyst is removed by filtration, the solution is cooled in an ice bath and 0.55 g of sodium hydroxide added.
- the mixture is left to react until the complete disappearance of the reagent and the reaction neutralised with 0.9 mL of acetic acid.
- the mixture is concentrated to residue and the oil is taken up with 25 mL of toluene.
- the solution is cooled in an ice bath, and 1.1 mL of 62% HBr (14.3 mmol) in water added dropwise, and the mixture left stirring until completion of the reaction. 2.5 mL of 12% sodium carbonate is added and the mixture stirred at RT, the phases are separated and the aqueous phase extracted with 5 mL of toluene.
- the organic solution is made to react with a mixture containing 3.0 g of triphenylphosphine (11 mmol) in 6.0 mL of methylene chloride. The mixture is stirred at RT for 18 hours. The mixture is then cooled to O 0 C, filtered, and the solid washed with 5.0 mL of toluene. 5.0 g (65%) of C 15 -Wittig salt with a purity- of 94% (HPLC A%) are obtained.
- Example 11 Astaxanthin 1 Into a suitably inertised reaction vessel are loaded 5.0 g of C 15 -Wittig salt (2) (8.4 mmol), 2,7- dimethylocta-2,4,6-trien-l,8-dialdehyde (3) (3.6 mmol) and 3.2 mL of butylene oxide in 25 mL of isopropanol. The reaction is kept refluxing for 18 hours, and subsequently the solid is filtered out. The crude product is isomerised by three successive rounds of re-crystallisation: the dark solid is dissolved in 25 mL of methylene chloride, l then the solution is refluxed and the solvent exchanged by distillation at atmospheric pressure with 36 mL of methanol. This procedure is repeated, and • the third re- crystallisation is performed using heptane in place of the methanol. 1.8 g (80%) of Astaxanthin are obtained with a purity of 96% (HPLC A%) .
Abstract
The present invention relates to a process for the preparation of intermediates useful in the synthesis of Astaxanthin, in particular C15-Wittig salts, but also 4-oxo-β-ionones, 3-hydroxy-4-oxo-β-ionones and the aryl esters thereof. 4-oxo-β-ionone is prepared by starting from a β-ionone by oxidation with bromates in the presence of iodine or iodide. 3-hydroxy-4-oxo-β-ionone is prepared in 4 steps, starting from 4 -oxo- β-ionone by oxidation with peracids; the aryl esters thereof are solids that are easily isolated and purified by crystallisation, and may be converted in 5 steps to C15-Wittig salts and finally, by the Wittig reaction, to Astaxanthin.
Description
Process for the synthesis of intermediates for the preparation of astaxanthin
Technical field of the invention The present invention relates to a process for the preparation of intermediates useful in the synthesis of Astaxanthin, in particular Ci5-Wittig salts, but also 4-oxo-β-ionones, 3-hydroxy-4-oxo-β-ionones and the aryl esters thereof. State of the art
Astaxanthin is a carotenoid found widely throughout nature (for example it is present as a pigment in numerous crustaceans) and is of significant commercial interest as a food additive; it is mainly used as a natural food-colouring for fish, in order to give the flesh a colour similar to that of salmon (for example salmon trout) . Even though initially, Astaxanthin was extracted from crushed crustacean shells, given the rather large quantities required on the global market, which is in continual expansion, it is currently more often produced by chemical synthesis.
All the major synthetic pathways for Astaxanthin 1 use two chemical synthons in the last step known as C15- Wittig salts £ and CiO-dialdehydes 3^ (see scheme 1) ,
which condense together through the Wittig reaction to give the final product .
Scheme i
2 3 1
The Cio-dialdehyde intermediate 3_ may be prepared by following the indications given in the UK patent GB 768172.
On the other hand, synthesis of the Ci5-Wittig salt intermediate 2 is rather more difficult . The current industrial synthetic processes for this intermediate start from a cheap and commercially available raw material known as isophorone, which has the following formula:
This is a complex multi-step process which also uses several raw materials and/or intermediates which have chemical stability and toxicity problems. Another interesting synthetic approach (see schema 2) , described in HeIv. Chim. Acta. 6.4 (1981), 2419-2435
and EP 5749, on the other hand uses β-ionone £, a relatively cheap raw material that is available commercially, which also has the advantage of having a 15 carbon atom backbone, much more complex than that of isophorone and having a chemical structure much closer to that of a Wittig salt £. β-ionone 4 is oxidised to 4-oxo-β-ionone j>, then transformed into the corresponding monoketal £, then oxidised in the presence of excess lead tetra-acetate in toluene to give 3-acetoxy-4-oxo-β-ionone monoketal "7 and then finally de-protected to give 3-acetoxy-4-oxo-β-ionone £ with an overall yield of 58% from j>. In the second part of the synthetic process, the key reaction is the transformation of 3-acetoy-4-oxo-β-ionone £ into the intermediate £, which is then converted to the Wittig salt £ by hydrolysis of the ester, rearrangement of the tertiary alcohol Ij) to the corresponding allyl bromide 11 and finally reaction with triphenylphosphine .
Scheme 2
11 10
However, 4-oxo-β-ionone !5 is obtained with modest yield (52%) from β-ionone Jt by oxidation with pyridinium chlorochromate (PCC) in DMSO. Furthermore, this process has additional problems for its 0 industrial application: firstly, the use of rather toxic and highly polluting chromium (VI) -based oxidants, and the purification of a number of intermediates by silica gel chromatography, a costly technique, and difficult to apply on a large 5 industrial scale.
In the literature, there are other methods for the direct oxidation of β-ionone 4 to 4-oxo-β-ionone I>, but they generally make use of reagents that are infeasible for industrial production, such as eerie 0 ammonium nitrate and iodine (Chem. Express (1991) , 6(2), 125-8), or chromium (VI) derivatives (Tetrahedron
(1992), 48(5), 953-62); in any case, the yields obtained rarely exceed 50%.
Furthermore, in the literature, there are several processes for the indirect oxidation of β-ionone. The work published in J. Chem. Soc. 1951, 1074 makes use of allylic bromination using NBS and oxidation with manganese dioxide, but the process requires 4 steps and the overall yield is low. In J. Am. Chem. Soc, 2003, 125, 3232-3233 α,β-enones are oxidised with high yield (80-90%) to 1,4-dienones. in heterogeneous phase with t-butyl hydroperoxide and palladium hydroxide on carbon; however, the application of this method to β- ionone 4_ has lead to a mixture of products, including 4-oxo-β-ionone !5 in percentages of less than 40%. Finally, US patent US 4209450 claims a process in which β-ionone 4_ is oxidised directly to give 4-oxo-β- ionone £> by means of a biphasic chloroform/aqueous sulphuric acid system, using as an oxidant a large excess of sodium chlorate, in the presence of catalytic quantities of iodine or sodium iodide: following reaction for 24 hours at 45°C, the product is isolated initially as a crude oil with a yield of 56% and subsequently purified by high vacuum fractional distillation to give 4-oxo-β-ionone EJ with a final yield of 40%. However, repetition of the
procedure reported in the aforementioned patent has not lead to the attainment of significant quantities of product (see example 1) .
Hence, there is nothing in the literature describing a synthetic process allowing the, attainment of 4-oxo-β- ionone j> by means of an industrially applicable process, i.e. characterised by acceptable yields, the use of cheap and non-toxic raw materials and a process that is simple and easy to industrialise. In relation to the synthesis of 3-acetoxy-4-oxo-β- ionone 8^ and the corresponding alcohol 3-hydroxy-4- oxo-β-ionone ,121, the only synthetic pathway described in the literature is that reported in HeIv. Chim. Acta
64 (1981) , 2419-2435 and EP 5749 (see scheme 2) .
This pathway has significant problems in relation to its industrial application, associated primarily with the use and the disposal of lead tetra-acetate. Furthermore, the intermediate 3-acetoxy-4-oxo-β-ionone j} has the characteristic of being a low melting point solid that is difficult to purify on the industrial scale. The US patent US 4963583 describes and claims esters of 3-hydroxy-4-oxo-β-ionone 121, that can be
used as antifungal agents, wherein the ester moiety is represented by an alkyl, cycloalkyl or alkoxyalkyl chain. In any case, this patent reports that compound 12 is prepared according to the directions in HeIv. Chim. Acta. 64 (1981), 2419-2435 and EP 5749 (US 4245109) .
However, there are no reports in the literature of an oxidation method for 4-oxo-β-ionone _5 to give 3- hydroxy-4-oxo-β-ionone 12. an<^ the esters thereof which can be applied industrially.
Furthermore, to date, there are no synthetic pathways available starting from β-ionone for the intermediate Ci5-Wittig salt 2_ which can conveniently be applied industrially. Brief description of the invention
The present invention relates to a process for the preparation of astaxanthin wherein the distinguishing feature is the process for the preparation of a C15- Wittig salt 2 starting from a β-ionone £, through the intermediates 3-hydroxy-4-oxo-β-ionone 12 and the aryl esters thereof. Said process is characterised by the use of cheap and non-toxic raw materials, it is simple and easily industrialisable and gives good molar yields. Furthermore, the aryl esters of 3-hydroxy-4- oxo-β-ionone "L2. have the characteristic of being
relatively high melting point solids, and can be purified by simple crystallisation from the corresponding reaction mixture and thus be obtained with such a degree of purity as to be able to be conveniently used in the synthesis of the intermediate Ci5-Wittig salt 2_ and thus Astaxanthin 3L. In the process of the invention, the β-ionone A is oxidised to 4-oxo-β-ionone !5 by means of a particularly advantageous method. Detailed description of the invention Synthesis of the Ci5-Wittig salt 2
It has surprisingly been found that it is possible to efficiently prepare the key intermediate for the synthesis of Astaxanthin 1, i.e. the Ci5-Wittig salt 2;, starting from a β-ionone 4>.
According to one first aspect of the invention, the process comprises an oxidation step of the β-ionone which allows it to be obtained with high yield. According to another particularly preferred aspect, the process comprises ten synthetic steps, but with the isolation of just two solid intermediate, namely the 4-oxo-β-ionone E> and the aryl ester of the 3- hydroxy-4-oxo-β-ionone ^£5 (see scheme 3) . The Ci5- Wittig salt 2_ is then used for the synthesis of Astaxanthin 1, according to the synthetic scheme known
in the art, i.e. through la Wittig condensation reaction with a CiO-dialdehyde 3_ (see schema 1) .
Schema 3
13
13 14 12 15
15 18 10
10 11
Synthesis of 4-oxo-β-ionone 5
It has surprisingly been found that it is possible to oxidise β-ionone £ to 4-oxo-β-ionone !>, directly and with good yield, using an alkaline metal or alkaline earth metal bromide as an oxidant in the presence of catalytic quantities of iodine or an alkaline metal or alkaline earth metal iodide and operating in an inert organic solvent in an acidic aqueous medium, which allows the in situ formation of bromic and/or iodic acid. The reaction is easily achieved by adding the bromate solution to the mixture constituted by the β- ionone £ dissolved in the organic solvent and an aqueous solution of iodide and acid. The bromate used is preferably selected from sodium bromate, potassium bromate and calcium bromate, more preferably sodium bromate. For a better outcome of the oxidation reaction, it is important that the quantity i of bromate used preferably be between 0.5 and 1.5 equivalents, more preferably between 0.9 and 1.1 equivalents.
The iodide used is preferably selected from sodium iodide and potassium iodide, and the quantity thereof is preferably between 0.05 and 1.0 equivalents, more preferably between 0.05 and 0.2 equivalents.
The organic solvent is selected from aliphatic and aromatic hydrocarbons, ethers and esters, chlorinated hydrocarbons, alcohols and polar aprotic solvents, preferably from hexane, cyclohexane, toluene, t-butyl methyl ether, THF, ethyl acetate, isopropyl acetate, methylene chloride, chloroform, chlorobenzene, dimethyl sulphoxide and methanol, more preferably methylene chloride. Depending on the organic solvent used, the reaction is carried out at a temperature between 0 and 1000C, preferably between 20 and 700C, more preferably between 30 and 400C. The reaction time is generally between 1 and 8 hours. The acidic aqueous medium is constituted by dilute aqueous solutions of mineral or organic acids, acid salts or a mixture of an acid and its corresponding salt so as to form a buffer solution. The acid is an inorganic acid, preferably selected from sulphuric acid, hydrochloric acid, phosphoric acid, sodium bisulphate, more preferably sodium bisulphate, or an organic acid, preferably selected from acetic acid, formic acid and citric acid. The quantity of acid is preferably between 0.1 and 1.0 equivalents, more preferably between 0.1 and 0.4 equivalents.
It has been observed experimentally that the oxidation reaction is more selective and clean when using aqueous solutions of relatively weak mineral acids, just like sodium bisulphate, where the system is buffered to pH 2-3 during the course of the entire reaction.
Using an aqueous solution of sodium- bisulphate, sodium bromate and potassium iodide and methylene chloride, and with careful selection of the reaction conditions, it is possible to achieve more or less complete conversion (greater than 95%) with a percentage of 4- oxo-β-ionone E> in the reaction mixture between 80% and 90%. The work-up comprises washing the aqueous phase with an aqueous solution of sodium bisulphite and sodium hydroxide, so as to reduce the iodine once more to iodide and break down any excess oxidant still present. The 4-oxo-β-ionone 5 is finally isolated by separation of the aqueous phase and evaporation of the organic solvent, and obtained with an overall yield between 85% and 95% and purity generally in excess of 90%.
The product may be purified by crystallisation from a suitable apolar organic solvent, preferably selected from pentane, hexane, heptane, or mixtures of the isomers thereof, more preferably a heptane isomer
mixture, and obtained with a yield between 70% and 80% with respect to β-ionone 4^ and purity in excess of 97%.
The aforementioned process has undoubted advantages with respect to that described in the US patent US 4209450 for the more or less quantitative conversion, the yield greater by at least 30 percentage points, the use of a stoichiometric quantity of oxidant and the much shorter reaction times. The process is furthermore characterised by the use of cheap, easily available, non-toxic raw materials, by simple execution and by high yield, all of which make it industrially applicable. Synthesis of 3-hydroxy-4-oxo-β-ionone 12 and the aryl esters thereof
4-oxo-β-ionone monoketal j> is prepared by reacting 4- oxo-β-ionone !5 with ethylene glycol in the presence of an acid catalyst and a dehydrating agent. The acid catalyst is an inorganic or organic acid, preferably selected from sulphuric, hydrochloric, hydrobromic, methanesulphonic and p-toluenesulphonic acid, more preferably p-toluenesulphonic acid. The dehydrating agent is preferably an orthoformate or an orthoacetate, more preferably ;trimethyl orthoformate.
It has surprisingly been found that it is possible to oxidise 4-oxo-β-ionone monoketal £ to 3-hydroxy-4-oxo- β-ionone 12^ avoiding the use of toxic oxidising agents. As reported in scheme 3, compound (J is converted into the corresponding trimethylsilylenolether 13_, which is oxidised by an organic peracid to give 4-oxo-β-ionone monoketal 14, which is directly de-protected during the reaction acid work-up to give 3-hydroxy-4-oxo-β-ionone 1£. The reaction sequence may be conveniently carried out by applying the so-called "telescoping" principle, i.e. without the isolation of the reaction intermediates 13. and 14. The reaction for the formation of trimethylsilyloxy-β- ionone 9-ethylene ketal 13_ may be conveniently carried out using a silanising agent preferably selected from chlorotrimethylsilane, bromotrimethylsilane, iodotrimethylsilane and hexamethyldisilazane, more preferably chlorotrimethylsilane, and an organic and organometallic base, preferably selected from triethylamine, diisopropylethylamine, lithium diisopropylamide, lithium bis (trimethylsilyl) amide, more preferably lithium diisopropylamide. The lithium diisopropylamide may be prepared conveniently and
economically in situ by reacting dϋsopropylamine and n-butyl lithium.
The oxidation reaction to 3-hydroxy-4-oxo-β-ionone 12^ is carried out using a peracid, preferably selected from peracetic acid, m-chloroperbenzoic acid, potassium monoperoxyphthalate, more preferably peracetic acid, or a peroxide or a hydroperoxide. The solution of peracetic acid in acetic acid is a commercially available and very economical substance. The reaction may be conveniently carried out in an organic solvent that is immiscible with water, preferably selected from aliphatic and aromatic hydrocarbons and chlorinated hydrocarbons, more preferably selected from toluene,' xylene, methylene chloride, chloroform, even more preferably in toluene. The intermediate 3-hydroxy-4-oxo-β-ionone 1£ is obtained after evaporation of the solvent as a crude oil with an overall 4-oxo-β-ionone. !> yield of 90-100% and purity of 65-75% (by HPLC) , corresponding to a molar weighted yield (HPLC wt %) of 60-65%. If desired, the intermediate may be purified by high vacuum distillation, but the purity of the crude product is sufficient for its use in the synthesis of the ester derivatives thereof.
The aforementioned oxidation method allows the attainment of 3-hydroxy-4-oxo-β-ionone jL2 by means of a process that is significantly improved with respect to that described in HeIv. Chim. Acta. 64 (1981) , 2419-2435 and EP 5749, in that it is characterised by superior yield and above all by the use of non-toxic raw materials without the environmental and disposal problems, a factor which is important for a process which is to be applied industrially. It has furthermore surprisingly been found that the esters of 3-hydroxy-4-oxo-β-ionone 12^ of general formula 15
wherein Ar is an optionally substituted aryl or heteroaryl group, are generally solid substances, some relatively high-melting and stable indefinitely under normal conditions. Furthermore, they can be isolated by simple crystallisation from the corresponding reaction mixture and therefore can be obtained with such a degree of purity as to be able to be used in
the synthesis of the intermediate Ci5-Wittig salt 2_ and therefore of Astaxanthin 1.
Ar is a phenyl group, optionally mono- or polysubstituted with groups preferably selected from alkoxyl, halogen, nitro, cyano and methyl, or a polyaryl group, preferably naphthyl. More preferably
Ar is a phenyl group, monosubstituted with a halogen or nitro, even more preferably with a chlorine atom.
Particularly preferred compounds include 3- (4- chlorobenzoyloxy) -4-oxo-β-ionone of formula 3^ and 3-
(1-naphthoyloxy) -4-oxo-β-ionone of formula 17.
16 17
These aryl esters may be synthesised starting from 3- hydroxy-4-oxo-β-ionone 3L^, using compounds of formula ArCOX, wherein Ar has the same meaning as above and X is selected from a halogen and RiCOO-, wherein Ri is an alkyl or aryl group, optionally substituted with a substituent that is the identical to or different from Ar. Preferably, acyl halides are used, wherein X is a
halogen, in that it is more reactive and more economical than the corresponding anhydrides of formula (ArCO)2O or mixed anhydrides. of formula ArCO-O- CORi, wherein Ri is different from Ar, but sterically hindered. In the case where acyl halides are used, a base is used as a hydrohalo acid acceptor which develops, preferably selected from a tertiary amine, for example pyridine or triethylamine, and an inorganic base in aqueous solution, thus operating under Schotten-Baumann conditions. The synthesis is conveniently carried out starting from a solution of 3-hydroxy-4-oxo-β-ionone V^ in a suitable inert organic solvent, such as for example toluene, containing a stoichiometric quantity of triethylamine and a catalytic quantity of 4-dimethylaminopyridine to accelerate the reaction. The product may be isolated with good yield and chemical purity by crystallisation from common organic solvents, preferably from alcoholic solvents, more preferably from methanol, ethanol and isopropanol.
3- (4-chlorobenzoyloxy) -4-oxo-β-ionone IS^ is a solid, relatively high-melting product (m.p. 128-132°C) , that can be easily synthesised starting from crude 3- hydroxy-4-oxo-β-ionone 1£ and 4-chlorobenzoyl chloride, a cheap raw material that is easily
available commercially. The product is easily- crystallised from methanol and obtained with an overall 4-oxo-β-ionone IS molar yield of 45-55% and purity generally in excess of 98% (by HPLC). 3- (4- chlorobenzoyloxy) -4-oxo-β-ionone lj∑ has been shown to be a particularly useful intermediate for the preparation of the Cis-Wittig salt 2_ and hence Astaxanthin 1. Besides 3- (4-chlorobenzoyloxy) -4-oxo-β-ionone 16, other aryl esters of formula 15 useful for the synthesis of Astaxanthin 1 have, been synthesised: benzoyl, 2-bromobenzoyl, 2-nitrobenzoyl, 3- chlorobenzoyl, 3,4-dichlorobenzoyl, 2-naphthoyl and 1- naphthoyl esters. The esters of 3-hydroxy-4-oxo-β-ionone 12^ of general formula IS1 are then converted in five steps to the Ci5- Wittig salt £ and, thereafter, to Astaxanthin 1 according to published procedures. Indeed, such esters are alkylated by reaction with a Grignard or lithium salt of acetylene in order to obtain the corresponding tertiary alcohol, which is selectively reduced by hydrogenation catalysed by Pd/CaCO3
(Lindlar) in order to obtain the esters of Ci5- vinylionol of general formula IB.- τ'le ester bond is hydrolysed under basic conditions in order to give Ci5-
vinylionol 3J), which is then reacted with concentrated hydrobromic acid to give allylic ' transposition and bromination. The Ci5-allylbromide of formula IJ. is converted by reacting with triphenylphosphine to give the C15-Wittig salt 22. The two synthons, denominated Ci5-Wittig salt £ and CiO-dialdehyde 3^ (see scheme 1) are converted into Astaxanthin I^ according to the instructions reported in HeIv. Chim. Acta. 64 (1981) , 2419-2435 and EP 5749 by double Wittig reaction in isopropanol in the presence of butylene oxide or, equivalently, in methanol in a basic environment . In conclusion, the synthetic process forming the subject of the present invention, allows the attainment of the Ci5-Wittig salt :2 by using a multi- step synthetic pathway, but consisting of the isolation of just two solid intermediates, namely the 4-oxo-β-ionone 5 and the ester of 3-hydroxy-4~oxo-β- ionone 1J5. The process is likewise characterised by good overall molar yield, by the use of raw materials that are easily obtainable in industrial quantities, and are cheap and non-toxic, by limited environmental impact, so that all the waste products obtained may be disposed of by means of standard incineration plants or biological treatment, and by no means least, simple execution and correct volumetry; all these aspects
making the process industrially applicable for the production of Astaxanthin. Examples
Example 1 (comparative) : 4-oxo-β-ionone 5 By following the instructions in example 1 of US patent US 4209450, a round-bottomed flask, under an atmosphere of nitrogen, is loaded with 4.8 g of β- ionone (25 mmol) and 125 mL of chloroform, then 13.3 g of sodium chlorate (125 mmol, 5 eq.) and 0.56 g of sodium iodide (3.7 mmol) dissolved in 50 mL of water are added. The solution is acidified with 55 μL of concentrated sulphuric acid. The reaction mixture is heated at 45°C for 24 hours, and the progress of the reaction monitored by GC/HPLC. 2 hours after addition, there are no traces of product in the reaction mixture, and after 24 hours, there is only 6.8%. Example 2; 4-oxo-β-ionone 5 I
Into a suitable reaction vessel, under an atmosphere of nitrogen, is loaded 100 g of 4-oxo-β-ionone (520 mmol) and 500 mL of methylene chloride; the reaction mixture is heated at 37°C and in the meantime a solution containing 9.6 g of potassium iodide (58 mmol) dissolved in 60 mL of water added, followed by a solution containing 17 g of sodium bisulphate monohydrate (123 mmol) dissolved in 35 mL of water. A
solution containing 79.2 g of sodium bromate (525 v rnmol) , dissolved in 250 mL of water, is added dropwise at 35-400C over as period of 2.5 hours. The reaction mix is stirred at 35-400C for 4 hours and the progress of the reaction monitored by GC/HPLC. Upon completion of the reaction, the system is cooled to 250C, the acidic aqueous phase separated and the organic phase treated with a solution containing 31 g of sodium hydroxide in 200 mL of water, then with a solution of 15.6 g of sodium hydroxide in 100. mL of water, then with a solution containing 15.0 mL of acetic acid and 1.5 g of sodium bisulphite in 100 mL of water and finally with 100 mL of water. The organic phase is treated with 10 g of acticarbone, filtered, and then concentrated to a residue under vacuum. 400 mL of heptane isomer mixture are added and the suspension heated to 35-400C, then cooled to 00C: the 4-oxo-β- ionone precipitate is then filtered, washed with 80 mL of heptane and then dried to constant weight under vacuum at 25-300C, to give 80.5 g of 4-oxo-β-Ionone (75%) with purity (as judged by HPLC) > 97%. Example 3: 4-oxo-β-ionone 9-ethylene ketal 6 Into a suitable reactor under ^nitrogen is loaded 80.5 g of 4-oxo-β-ionone (390 mmol) , 45 mL of methylene chloride and 161 mL of ethylene glycol (2.88 mol) . The
suspension is stirred at RT for 30 ', then 0.74 g of p- toluenesulphonic acid (3.90 mmol) added. A solution constituted by 50.5 mL of trimethyl orthoformate (460 mmol) and 0.105 mL of pyridine (1.3 mmol) is added dropwise at 20-250C over a period of 30-40'. Upon completion of the reaction (GC) the reaction mixture is poured into a mixture constituted by 9.65 g of sodium carbonate dissolved in 80 mL of water and 80 mL of heptane isomer mixture. The phases are separated and the aqueous phase extracted twice with 80 mL of heptane and the organic phases washed twice with 80 mL of water. The organic phase is cooled to 100C and treated with a solution of 68 mL of methanol, 130 mL of water with 11 mL of glacial acetic acid, while the temperature is maintained at 100C. After 7 hours, GC analysis shows the quantity of 4-oxo-β-ionone 9- ethylene ketal present to be 92-93%. The mixture is poured into a solution of 25 ϊ7 g of sodium carbonate in 225 mL of water. The aqueous phase is separated and the organic phase treated with 8.05 g of anhydrous sodium sulphate and 8.05 g of acticarbone, the suspension is stirred at RT for 30' and then filtered. The solution is evaporated to half volume (the solution can contain at most 1 volume of heptane) and is used as such in the subsequent reaction.
Example 4: 4-trimethylsilyloxy~β-ionone 9-ethylene ketal 13 i
Into a carefully dehydrated suitable reaction vessel under nitrogen is added 66 mL of diisopropylamine (468 iranol) and 95 mL of tetrahydrofuran. A solution of 165 mL of 25% n-butyl lithium in heptane (460 mmol) is added dropwise at 200C over 45-60'. The reaction mixture is stirred at 20° for 30 ', then the solution containing the crude 4-oxo-β-ionone 9-ethylene ketal obtained according to example 3 is added dropwise over 1 hour at 20-250C. After 45', 61 mL of chlorotrimethylsilane (456 mmol) is added over 30-40 min. at 20-250C. The reaction- mixture is stirred for at least 30' under nitrogen, then the solvent is evaporated under vacuum to leave a dense residue, which is then diluted with 160 mL of toluene; the inorganic salts present are filtered and washed with toluene. The solution containing crude 4- trimethylsilyloxy-β-ionone 9-ethylene ketal is stored under nitrogen and used directly in the following step.
Example 5; 3-hydroxy-4-oxo-β-ionone .12
Into a suitable reaction vessel, under an atmosphere of nitrogen, is loaded 106 mL pf paracetic acid in 32% acetic acid (507 mmol) and 160 mL of toluene; the
temperature of the mixture is adjusted to -150C, and at that temperature, the toluene solution containing crude 4-trimethylsilyloxy-β-ionone 9-ethylene ketal prepared in example 4 is added dropwise over 1-3 hours. The reaction mixture is stirred at T < -100C for one hour and, upon completion of the reaction, a solution of 6.1 iϊiL of 32% hydrochloric acid in 80 mL of water added. The reaction mix is stirred for 1.5 hours then neutralised with approx. 190 mL of 30% sodium hydroxide. The organic phase is separated and the aqueous phase is extracted with 60 mL of toluene; the combined organic phases are washed with a 80 mL solution containing 1.6 g of sodium bisulphite in water (15 mmol) . The organic phases are dried by evaporation of approx. 1/3 of the solvent present, so as to obtain a clear solution, which is used directly in the following step.
Example 6: 3- (4-chlorobenzyloxy) -4-oxo-β-ionone 16 Into a suitable reaction vessel, under a nitrogen atmosphere, is loaded, the toluene solution of 3- hydroxy-4-oxo-β-ionone prepared according to example 5, 51.5 mL of triethylamine and 0.80 g of 4- dimethylaminopyridine; 41.5 mL of p-chlorobenzoyl chloride is added dropwise at 20-25° over the course of one hour and the reaction mix stirred for 3-4
hours. Upon completion of the reaction 80 mL of water are added and the mixture heated at 4O0C for 301. The p-chlorobenzoic anhydride by-product is eliminated by filtration while hot. The organic phase is separated and the aqueous phase subsequently extracted with 60 mL of toluene. The combined organic phases are concentrated to residue under vacuum, taken up with 135 mL of methanol and the solvent evaporated once more under vacuum. The solid residue is then taken up with 400 mL of methanol and 1 mL of triethylamine; the suspension is then refluxed and stirred so as to give a solution which is gradually cooled to O0C, thus achieving the precipitation of the product . The precipitate is filtered, washed with 75 mL of cold methanol and dried to constant weight, 73.2 g of 3-β- chlorobenzyloxy) -4-oxo-β-ionone are obtained (52% with respect to 4-oxo-β-ionone) , m.p. = 128-132°C.
1H-NMR (300 MHz, CDCl3): δ (ppm) = 1.22 (s, 3H, CH3 (la) ring) ; 1.42 (s, 3H, CH3 (lb) ring) ; 1.85 (d, 0.9 Hz, 3H, CH3 (5) ring); 2.15-2.30 (m, 2H, CH2 (2) ring) ; 2.36 (s, 3H, CH3 chain) ; 5.76 (dd, IH, 3 Hz, 12 Hz, CH(3)ring); 6.24 (d, IH, 16.5 Hz, CHvin C=O); 7.23 (dd, IH, 0.9Hz; 16.5HZ, CHvin chain); 7.41-7.44 (m, 2H, 3,3" Ph); 8.01-8.04 (m, 2H, 2,2' Ph).
13C-NMR (75 MHz, CDCl3) : δ (ppm) = 13.6; 25.9; 28.2; 30.1; 37.0; 42.7; 71.5; 128.1; 128.7; 130.3; 131.3; 134.1; 139.2; 139.7; 157.2; 165.0; 193.4; 197.7 Example 7: 3-hydroxy-4-oxo-β-ionone 12 Into a suitable reactor under nitrogen are loaded 234 g of 4-oxo-β-ionone (1.135 mol) , 130 mL of methylene chloride and 468 mL of ethylene glycol (8.38 mol) . The suspension is stirred at RT for 30 ', then 2.15 g of p- toluenesulphonic acid (11 mmbl) added. A solution constituted by 180 mL of trimethyl orthoformate (1.644 mmol) and 0.305 mL of pyridine (3.8 mol) is added dropwise at 20-250C over a period of 30-40'. Upon completion of the reaction (GC) the reaction mixture is poured into a solution constituted by 28.0 g of sodium carbonate, 235 mL of water and 235 mL of heptane isomer mixture. The organic' phase is separated and the aqueous phase extracted twice with 235 mL of heptane and the organic phases washed twice with 235 mL of water. The organic phase is cooled to 100C and treated with a solution of 200 mL of methanol, 375 mL of water with 32.5 mL of glacial acetic acid (567 mmol) , while the temperature is maintained at 100C. Generally, after 5 hours, the 4-oxo-β-ionone 9- ethylene ketal (S reaches a quantity in excess of 90% (as judged by GC) . The mixture is poured into a
solution of 74.7 g of sodium carbonate in 655 mL of water, the phases are separated and the organic phase treated with 23.4 g of anhydrous sodium sulphate and 23.5 g of acticarbone; the suspension is stirred at 20-25° C for 30' and then filtered. The solution is evaporated to half volume, to give 430 g of heptane solution which is added under nitrogen to a solution of lithium diisopropylamide, previously prepared by treating 192 mL of diisopropylamine (1.362 mol) in 280 mL of tetrahydrofuran at 20°C with a solution of 480 mL of 25% n-butyl lithium in heptane (1.339 mol) . The resulting solution is stirred for 45 ' at 20°C, then 177 mL of chlorotrimethylsilane (1.170 mol) added dropwise at 20-25°C over 40'. The reaction mix is stirred for 30', then the solvent evaporated under vacuum to a dense residue, which is then diluted with 460 mL of toluene; the inorganic salts present are filtered and washed with 180 mL of toluene. The resulting solution is transferred under an atmosphere of nitrogen into a dropping funnel and then added, over the course of an hour, to a mixture thermostated at -15°C consisting of 310 mL of peracetic acid in 32% acetic acid (1.475 mol) and 160 mL of toluene. Upon completion of the reaction, 12 mL of 32% hydrochloric acid in 235 mL of water are added. The reaction mix is
stirred for 1.5 hours, then, upon completion of the reaction (as judged by HPLC analysis) neutralised with approx. 320 mL of 30% sodium hydroxide. The organic phase is separated and the aqueous phase is extracted with 175 mL of toluene; the combined organic phases are washed with a 235 mL solution containing 4.6 g of sodium bisulphite in water (45 mmol) . The organic phase is concentrated to an oily residue, to give 135 g of crude 3-hydroxy-4-oxo-β-ionone (53% with respect to 4-oxo-β-ionone) with a purity of 65% (as judged by HPLC) , which is then used crude directly in the subsequent esterification reactions. Example 8: 3- (1-naphthoyloxy) -4-oxo-β-ionone 17 Into a suitable reaction vessel under nitrogen are loaded 4.0 g of 3-hydroxy-4-oxo-β-ionone prepared in example 8 (18 mmol theoretical) dissolved in 14 mL of toluene, 2.4 mL of triethylamine (17.2 mmol) and 0.05 g of 4-dimethylaminopyridine; 2.34 mL of 1-naphthoyl chloride (20.3 mmol) dissolved in 5 mL of methylene chloride is added dropwise at 20-25° over 30' and the mixture stirred at 20-25°C for 3-4 hours. Upon completion of the reaction (as judged by HPLC) , 10 mL of water are added and the mixture heated at 40°C for 30". The p-chlorobenzoic anhydride by-product is eliminated by filtration while hot. The organic phase
is separated and washed with 15 mL of 5% acetic acid and subsequently with 15 mL of 5% sodium bicarbonate. The organic phase is concentrated to residue under vacuum and the resulting oil -purified by silica gel column chromatography (eluent heptane/t-butyl methyl ether 6:4), to give 1.5 g of 3- (1-naphthoyloxy) -4-oxo- β-ionone (25% with respect to 4-oxo-β-ionone) as a yellow solid with purity of 90% (as judged by GC) and m.p. = 920C. 1H-NMR (300 MHz, CDCl3): δ (ppm) = 1.23 (s, 3H, CH3 (Ia) ring) ; 1.46 (s, 3H, CH3 (lb) ring) ; 1.89 (d, 1.2 Hz, 3H, CH3(5)ring); 2.22-2.34 (m, 2H, CH2 (2) ring) ; 2.36 (s, 3H, CH3 chain); 5.93 (dd, IH, 6.9 Hz, 12.9 Hz, CH(3)ring); 6.25 (d, IH, 15.2 Hz, CHvin C=O) ; 7.24 (dd, IH, 1.1 Hz, 15.2 Hz^ CHVin chain); 7.48-7.65
(m, 3H, CH5.6.7 πaph. ring) ; 7.90-7.87 (m, IH, CH3 πaph. ring)
; 8.04-8.02 (m, IH, CH4 πaph. ring) ; 8.28-8.26 (dd, IH,
1.2 Hz, 7.2 Hz, CH8 napll. ring) ; 8.35-8.92 (m, IH, CH2 naph. ring/ 13C-NMR (75 MHz, CDCl3) : δ (ppm) = 13.7; 25.9;
28.2; 30.1; 37.0; 42.7; 71.3; 124.5; 125.8; 126.2; 126.8; 127.7; 128.4; 130.3; 130.4; 131.3; 133.5; 133.7; 134.1; 139.3; 157.2; 166.8; 193.7; 197.1 Example 9 : 3 - (2-bromobenzoyloxy) -4-oxo-β-ionone
Into a suitable reaction vessel under nitrogen are loaded 8.0 g of oil originating from the previous reaction (32 mmol theoretical) dissolved in 40 πiL of toluene, 4.5 mL of triethylamine (32 mmol) and 0.05 g of 4-dimethylaminopyridine; 3.6 mL of 2-bromobenzoyl chloride (27.5 mmol) dissolved in 5 mL of toluene is added dropwise at 20-25° over 30' and the mixture stirred at 20-25°C for 3-4 hours. Upon completion of the reaction (as judged by HPLC) , 10 mL of water are added and the mixture heated at 40°C for 301. The p- chlorobenzoic anhydride by-product is eliminated by filtration while hot. The organic phase is separated and washed with 15 mL of 5% . acetic acid and subsequently with 15 mL of 5% sodium bicarbonate. The organic phase is concentrated to residue under vacuum and the resulting oil purified by silica gel column chromatography (eluent heptane/t-butyl methyl ether 6:4), to give 3.8 g of 3- (2-bromobenzoyloxy) -4-oxo-β- ionone (30% with respect to 4-oxo-β-ionone) as a yellow oil with purity of 96% (as judged by GC) . Example 10; [5- (4-hydroxy-2, 6, β.-trimethyl-3-oxo- 1-cyclohexen-l-yl) -3-methyl-2, 4- pentadienyl] triphenylphosphonium bromide "Ci5-Wittig salt" 2
Into a suitable reaction vessel, under nitrogen, is loaded 35 mL of 5% ethinylmagnesium chloride (17.5 iranol) in toluene and THF (Chemetall) , the mixture is cooled to -100C and a solution containing 5.0 g of 3- (4-chlorobenzyloxy) -4-oxo-β-ionone (13.8 mmol) in v. toluene and THF is added dropwise. The mixture is stirred until the reaction is completed and then quenched with 40 mL of 10% acetic acid. The mixture is stirred, and then the phases allowed to separate, then the organic phase is washed with 25 mL of 5% NaHCO3. The mixture is then evaporated to residue and then taken up with 50 mL of methanol. The solution is loaded into a boiler along with 8.64 mL of a 0.75% w/v solution of dimethylethanolamine in hexane, 8.5 mL of a solution of 0.0125% 1,2-bis- (hydroxyethylthio) - ethanol in ether and 150 mg of-^ Lindlar' s catalyst. The mixture is hydrogenated at 1 bar at RT. The catalyst is removed by filtration, the solution is cooled in an ice bath and 0.55 g of sodium hydroxide added. The mixture is left to react until the complete disappearance of the reagent and the reaction neutralised with 0.9 mL of acetic acid. The mixture is concentrated to residue and the oil is taken up with 25 mL of toluene. The solution is cooled in an ice bath, and 1.1 mL of 62% HBr (14.3 mmol) in water added
dropwise, and the mixture left stirring until completion of the reaction. 2.5 mL of 12% sodium carbonate is added and the mixture stirred at RT, the phases are separated and the aqueous phase extracted with 5 mL of toluene. The organic solution is made to react with a mixture containing 3.0 g of triphenylphosphine (11 mmol) in 6.0 mL of methylene chloride. The mixture is stirred at RT for 18 hours. The mixture is then cooled to O0C, filtered, and the solid washed with 5.0 mL of toluene. 5.0 g (65%) of C15-Wittig salt with a purity- of 94% (HPLC A%) are obtained.
Example 11 : Astaxanthin 1 Into a suitably inertised reaction vessel are loaded 5.0 g of C15-Wittig salt (2) (8.4 mmol), 2,7- dimethylocta-2,4,6-trien-l,8-dialdehyde (3) (3.6 mmol) and 3.2 mL of butylene oxide in 25 mL of isopropanol. The reaction is kept refluxing for 18 hours, and subsequently the solid is filtered out. The crude product is isomerised by three successive rounds of re-crystallisation: the dark solid is dissolved in 25 mL of methylene chloride, lthen the solution is refluxed and the solvent exchanged by distillation at atmospheric pressure with 36 mL of methanol. This procedure is repeated, and • the third re-
crystallisation is performed using heptane in place of the methanol. 1.8 g (80%) of Astaxanthin are obtained with a purity of 96% (HPLC A%) .
Claims
1. A process for the preparation , of astaxanthin by means of the preparation of the intermediate of formula:
where X is selected from Cl, Br or I; comprising the steps of: v a) oxidising the β-ionone to give the corresponding 4- oxo-β-ionone; b) transforming the 4-oxo-β-ionone obtained in part a) into 3-hydroxy-4-oxo-β-ionone and/or an ester thereof; c) transforming the 3-hydroxy-4-oxo-β-ionone and/or the ester thereof into a Ci5-Wittig salt, and then into astaxanthin; wherein in step a) the oxidation of the β-ionone
2. The process according to l claim 1 wherein X is bromine .
3. The process according to claims 1 or 2 wherein in step a) the oxidation of a β-ionone
4. The process according to any of the claims 1 to 3 wherein in step a) the bromate is selected from potassium bromate, calcium bromate and sodium bromate, preferably sodium bromate.
5. The process according to any of the claims 1 to 4 wherein in step a) the quantity of bromate is between 0.5 and 1.5 equivalents, preferably between 0.9 and 1.1 equivalents .
6. The process according to any of the claims 1 to 5 wherein in step a) the iodide is selected from sodium iodide and potassium iodide.
7. The process according to any of the claims 1 to 6 wherein in step a) the quantity of iodide is between 0.05 and 1.0 equivalents, more preferably between 0.05 and 0.2 equivalents.
8. The process according to any of the claims 1 to 7 wherein in step a) the organic solvent is selected from aliphatic and aromatic hydrocarbons, ethers and esters, chlorinated hydrocarbons, alcohols and polar aprotic solvents, preferably from hexane, cyclohexane, toluene, t-butyl methyl ether, THF, ethyl acetate, isopropyl acetate, methylene chloride, chloroform, chlorobenzene, dimethyl sulphoxide and methanol, more preferably methylene chloride.
9. The process according to any of the claims 1 to 8 wherein in step a) depending on the organic solvent used, the reaction is carried out at a temperature between 0 and 1000C, preferably between 20 and 700C, more preferably between 30 and 400C.
10. The process according to any of the claims 1 to 9 wherein in step a) the aqueous acidic medium is constituted by dilute aqueous solutions of mineral or organic acids, acid salts or a mixture of an acid and its corresponding salt so as to form a buffer solution.
11. The process according to claim 10 wherein the acid is an inorganic acid, preferably selected from sulphuric acid, hydrochloric acid, phosphoric acid, sodium bisulphate, more preferably sodium bisulphate, or an organic acid, preferably selected from acetic acid, formic acid and citric acid.
12. The process according to claims 10 or 11 wherein the acid is used in quantities between 0.1 and 1.0 equivalents, preferably between 0.1 and 0.4 equivalents .
13. The process according to any of the claims 1 to
12, wherein in step a) the reaction is carried out by adding the bromate solution onto the mixture constituted by a β-ionone dissolved in the organic solvent and an aqueous solution of iodide and acid.
14. The process according to any of the claims 1 to
13, wherein in step a) the 4-oxo-β-ionone is purified by crystallisation from an apolar organic solvent, preferably selected from pentane, hexane, heptane, or
a mixture of the isomers thereof, more preferably a heptane isomer mixture.
15. The process according to any of the claims 1 to 14 wherein step b) consists of the step of: bl) reacting the 4-oxo-β-ionone:
with ethylene glycol in the presence of an acid catalyst and a dehydrating agent in order to obtain the 4-oxo-β-ionone monoketal of formula:
1.6. The process according to claim 15 wherein step b) further comprises the step of: b2) oxidising the monoketal obtained from step bl) with lead tetra-acetate to give the 3-acetoxy-4-oxo-β- ionone monoketal; b3) de-protecting the 3-acetoxy-4-oxo-β-ionone monoketal by treating the reaction mixture with an aqueous acid to give the 3-acetoxy-4-oxo-β-ionone.
17. The process according to claims 15 or 16, wherein in step bl) the acid catalyst is an inorganic or organic acid, preferably selected from sulphuric,
hydrochloric, hydrobromic, methanesulphonic and p- toluenesulphonic acid, more preferably p- toluenesulphonic acid.
18. The process according to any of the claims 15 to 17, wherein in step bl) the dehydrating agent is an orthoformate or an orthoacetate, more preferably trimethyl orthoformate .
19. The process according to claim 15 wherein step b) i further comprises the step of: b2) reacting the 4-oxo-β-ionone 9-ethylene ketal, obtained from step b) , with a silanising agent and an organic or organometallic base in order to obtain the 4-trimethylsilyloxy-β-ionone 9-ethylene ketal of formula
b3) reacting the 4-trimethylsilyloxy-β-ionone 9- ethylene ketal with a peracid, a peroxide or a hydroperoxide and subsequently treat the reaction mixture with an aqueous acid in order to obtain the 3- hydroxy-4-oxo-β-ionone of formula:
b4) reacting the 3-hydroxy-4-oxo-β-ionone with a compound of formula ArCOX, in cui Ar is an optionally substituted aryl or heteroaryl group, and X is selected from halogen and R1COO-, wherein Ri is an optionally substituted alkyl or aryl group, identical or otherwise to Ar, to give the corresponding ester:
20. The process according to any of the claims 1 to 19 wherein step c) consists of the steps of: cl) transforming the ester of 3-hydroxy-4-oxo-b-ionone into the corresponding tertiary alcohol intermediate; c2) hydrolysing the ester group; c3) rearranging the tertiary alcohol to the corresponding allyl halide; c4) treating the halide obtained from step c3) with triphenylphosphine to give the Ci5-Wittig salt;
c5) condensing the Ci5-Wittig salt with Cio-dialdehyde to give astaxanthin.
21. The process for the preparation of 4-oxo-β-ionone of formula:
starting from the β-ionone of formula
by oxidation with an alkaline metal or alkaline earth metal bromate in the presence of iodine or an alkaline metal or alkaline earth metal iodide, characterised in that said bromate is used in quantities between 0.5 and 1.5 equivalents.
22. A process for the preparation of astaxanthin by means of the preparation of the intermediate of formula :
where X is selected from Cl, Br or I; comprising the steps of: a) oxidising the β-ionone to give the corresponding 4- oxo-β-ionone; b) transforming the 4-oxo-β-ionone obtained in part a) into an ester of 3-hydroxy-4-oxo-β-ionone; c) transforming the ester of 3-hydroxy-4-oxo-β-ionone into the Ci5-Wittig salt and then into astaxanthin; wherein step b) consists of, among others, the following steps : : b2) reacting the 4-oxo-β-ionone 9-ethylene ketal with a silanising agent and an organic or organometallic base in order to obtain the 4-trimethylsilyloxy-β- ionone 9-ethylene ketal of formula
b3) reacting the 4-trimethylsilyloxy-β-ionone 9- ethylene ketal with a peracid, a peroxide or a hydroperoxide and subsequently treat the reaction mixture with an aqueous acid in order to obtain the 3- hydroxy-4-oxo-β-ionone of formula:
b4) reacting the 3-hydroxy-4-oxo-β-ionone with a compound of formula ArCOX, in cui.Ar is an optionally substituted aryl or heteroaryl group, and X is selected from halogen and RiCOO-, wherein Rx is an optionally substituted alkyl or aryl group, identical or otherwise to Ar, to give the corresponding ester:
23. The process according to claim 22 wherein step b) comprises the step of: bl) reacting the 4-oxo-β-ionone:
with ethylene glycol in the presence of an acid catalyst and a dehydrating agent in order to give the 4-oxo-β-ionone 9-ethylene ketal of formula:
24. The process according to claims 22 or 23, wherein in step b2) the silanising agent is selected from chlorotrimethylsilane, bromotrimethylsilane, iodotrimethylsilane and hexamethyldisilazane, preferably chlorotrimethylsilane .
25. The process according to any of the claims 22 to
24, wherein in step b2) the organic or organometallic base is selected from triethylamine, diisopropylethylamine, lithium diisopropylamide, lithium bis (trimethylsilyl) amide, preferably lithium diisopropylamide, also prepared "in situ by reacting diisopropylamine and n-butyl lithium.
26. The process according to any of the claims 22 to
25, wherein in step b3) the peracid is selected from
peracetic acid, m-chloroperbensoic acid, potassium monoperoxyphthalate, preferably peracetic acid.
27. The process according to any of the claims 22 to 26, wherein step b3) is carried .out in an organic solvent immiscible with water, preferably selected from aliphatic and aromatic hydrocarbons and chlorinated hydrocarbons .
28. The process according to claim 27, wherein the organic solvent is selected from toluene, xylene, methylene chloride, chloroform, more preferably toluene .
29. The process according to any of the claims 22 to 28, wherein in step b4) X is halogen.
30. The process according to any of the claims 22 to 29 for the preparation of 3- (4-chlorobenzyloxy) -4-oxo- β-ionone, wherein in step b4) the compound of formula ArCOX is 4-chlorobenzoyl chloride.
31. The process according to any of the claims 22 to 30 for the preparation of 3- (1-naphthoyloxy) -4-oxo-β- ionone, wherein in step b4) the compound of formula ArCOX is 1-naphthoyl chloride. i
32. The process according to any of the claims 22 to 31, wherein the product obtained from step b4) is purified by crystallisation from alcoholic solvents,
preferably selected from methanol, ethanol and isopropanol .
33. The process according to any of the claims 22 to 32 wherein in step a) the β-ionone is oxidised to 4- oxo-β-ionone by means of pyridinium chlorochrornate, or eerie ammonium nitrate and iodine, or chromium (VI) derivatives .
34. Compounds of general formula
wherein Ar is an optionally substituted aryl or heteroaryl group .
35. The compounds according to claim 34 wherein Ar is a phenyl group, optionally lmono- or polysubstituted with groups preferably selected from alkoxyl, halogen, nitro, cyano and methyl, or a polyaryl group, preferably naphthyl .
36. The compounds according to claims 34 or 35 wherein Ar is a phenyl group mono-substituted with halogen or nitro, preferably with a chlorine atom.
37. 3- (4-chlorobenzoyloxy) -4-oxo-β-ionone
38. 3- (1-naphthoyloxy) -4-oxo-β-ionone
39. Use of the compounds claimed in claims 34 to 38 for the preparation of Astaxanthin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT002486A ITMI20052486A1 (en) | 2005-12-23 | 2005-12-23 | INTERMEDIATE SYNTHESIS PROCEDURE FOR THE PREPARATION OF ASTAXANTIN |
ITMI2005A002486 | 2005-12-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007072529A2 true WO2007072529A2 (en) | 2007-06-28 |
WO2007072529A3 WO2007072529A3 (en) | 2007-11-22 |
Family
ID=38006882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT2006/000835 WO2007072529A2 (en) | 2005-12-23 | 2006-12-04 | Process for the synthesis of intermediates for the preparation of astaxanthin |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR058750A1 (en) |
IT (1) | ITMI20052486A1 (en) |
WO (1) | WO2007072529A2 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101805249A (en) * | 2010-04-07 | 2010-08-18 | 湖南中烟工业有限责任公司 | Method for synthesizing oxo-alpha-ionone or oxo-beta-ionone |
US7919527B2 (en) | 2002-02-25 | 2011-04-05 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
JP2011521929A (en) * | 2008-05-30 | 2011-07-28 | ディーエスエム アイピー アセッツ ビー.ブイ. | Crystalline form of astaxanthin |
JP2011524915A (en) * | 2008-06-18 | 2011-09-08 | レクシコン ファーマシューティカルズ インコーポレイテッド | Solid form of (1R, 2S, 3R) -1- (2- (isoxazol-3-yl) -1H-imidazol-4-yl) butane-1,2,3,4-tetraol and method of use thereof |
US8030350B2 (en) | 2005-02-24 | 2011-10-04 | Diffusion Pharmaceuticals Llc | Trans carotenoids, their synthesis, formulation and uses |
US8206751B2 (en) | 2007-10-31 | 2012-06-26 | Diffusion Pharmaceuticals Llc | Class of therapeutics that enhance small molecule diffusion |
US8269027B2 (en) | 2002-02-25 | 2012-09-18 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
WO2013068465A2 (en) | 2011-11-09 | 2013-05-16 | Basf Se | Method for producing oxo-vinyl-ionol and o-protected derivatives thereof |
CN103245658A (en) * | 2013-04-23 | 2013-08-14 | 山西省食品质量安全监督检验研究院 | Fast detection method of bromate in bread |
WO2015067706A1 (en) * | 2013-11-07 | 2015-05-14 | Dsm Ip Assets B.V. | Process for the purification of astaxanthin |
WO2015067705A1 (en) * | 2013-11-07 | 2015-05-14 | Dsm Ip Assets B.V. | Process for the purification of astaxanthin |
WO2015067703A1 (en) * | 2013-11-07 | 2015-05-14 | Dsm Ip Assets B.V. | Process for the purification of astaxanthin |
WO2015067711A1 (en) * | 2013-11-07 | 2015-05-14 | Dsm Ip Assets B.V. | Process for the purification of astaxanthin |
WO2015067707A1 (en) * | 2013-11-07 | 2015-05-14 | Dsm Ip Assets B.V. | Process for the purification of astaxanthin |
US9061982B2 (en) | 2011-11-09 | 2015-06-23 | Basf Se | Process for the preparation of oxovinylionol and its O-protected derivatives |
US9758500B2 (en) | 2012-04-16 | 2017-09-12 | Basf Se | Process for the preparation of (3E, 7E)-homofarnesol |
CN107739390A (en) * | 2017-09-29 | 2018-02-27 | 上虞新和成生物化工有限公司 | A kind of synthetic method of astaxanthin intermediate |
US10016384B2 (en) | 2010-06-02 | 2018-07-10 | Diffusion Pharmaceuticals Llc | Oral formulations of bipolar trans carotenoids |
US10130689B2 (en) | 2009-06-22 | 2018-11-20 | Diffusion Pharmaceuticals Llc | Diffusion enhancing compounds and their use alone or with thrombolytics |
CN109503545A (en) * | 2018-11-30 | 2019-03-22 | 彩客化学(沧州)有限公司 | A kind of preparation method of 1,4- cyclohexanedione monoethylene acetal |
CN111302925A (en) * | 2020-03-16 | 2020-06-19 | 万华化学集团股份有限公司 | Method for preparing cyclic α -unsaturated ketone |
CN112409155A (en) * | 2020-10-28 | 2021-02-26 | 肇庆巨元生化有限公司 | Preparation method of 4-oxo-beta-ionone |
US11185523B2 (en) | 2016-03-24 | 2021-11-30 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer |
CN114940644A (en) * | 2022-06-20 | 2022-08-26 | 万华化学集团股份有限公司 | Crystallization method of 2, 7-dimethyl-2, 4, 6-octatriene-1, 8-dialdehyde |
-
2005
- 2005-12-23 IT IT002486A patent/ITMI20052486A1/en unknown
-
2006
- 2006-12-04 WO PCT/IT2006/000835 patent/WO2007072529A2/en active Application Filing
- 2006-12-26 AR ARP060105795A patent/AR058750A1/en not_active Application Discontinuation
Non-Patent Citations (2)
Title |
---|
BECHER E ET AL: "SYNTHESE VON ASTAXANTHIN AUS BETA-JONON. I. ERSCHLIESSUNG DER ENANTIOMEREN C15-WITTIGSALZE DURCH CHEMISCHE UND MIKROBIOLOGISCHE RACEMATSPALTUNG VON (PLUS OR MINUS)-3-ACETOXY-4-OXO-BETA-JONON SYNTHESIS OF ASTAXANTHIN FROM BETA-IONONE. I. A ROUTE TO THE E" HELVETICA CHIMICA ACTA, VERLAG HELVETICA CHIMICA ACTA. BASEL, CH, vol. 64, no. 7, 1981, pages 2419-2435, XP008052045 ISSN: 0018-019X * |
KIM, TONG HEI ET AL: "Selective oxidation reaction at 3-position of .alpha.- and .beta.-ionones" CHEMISTRY EXPRESS , 6(2), 125-8 CODEN: CHEXEU; ISSN: 0911-9566, 1991, XP009084325 * |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7919527B2 (en) | 2002-02-25 | 2011-04-05 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
US8269027B2 (en) | 2002-02-25 | 2012-09-18 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
US11278621B2 (en) | 2005-02-24 | 2022-03-22 | Diffusion Pharmaceuticals Llc | Trans carotenoids, their synthesis, formulation and uses |
US8030350B2 (en) | 2005-02-24 | 2011-10-04 | Diffusion Pharmaceuticals Llc | Trans carotenoids, their synthesis, formulation and uses |
US9950067B2 (en) | 2005-02-24 | 2018-04-24 | Diffusion Pharmaceuticals, LLC | Trans carotenoids, their synthesis, formulation and uses |
US8206751B2 (en) | 2007-10-31 | 2012-06-26 | Diffusion Pharmaceuticals Llc | Class of therapeutics that enhance small molecule diffusion |
JP2011521929A (en) * | 2008-05-30 | 2011-07-28 | ディーエスエム アイピー アセッツ ビー.ブイ. | Crystalline form of astaxanthin |
JP2011524915A (en) * | 2008-06-18 | 2011-09-08 | レクシコン ファーマシューティカルズ インコーポレイテッド | Solid form of (1R, 2S, 3R) -1- (2- (isoxazol-3-yl) -1H-imidazol-4-yl) butane-1,2,3,4-tetraol and method of use thereof |
US10130689B2 (en) | 2009-06-22 | 2018-11-20 | Diffusion Pharmaceuticals Llc | Diffusion enhancing compounds and their use alone or with thrombolytics |
US11147859B2 (en) | 2009-06-22 | 2021-10-19 | Diffusion Pharmaceuticals Llc | Diffusion enhancing compounds and their use alone or with thrombolytics |
CN101805249A (en) * | 2010-04-07 | 2010-08-18 | 湖南中烟工业有限责任公司 | Method for synthesizing oxo-alpha-ionone or oxo-beta-ionone |
US10016384B2 (en) | 2010-06-02 | 2018-07-10 | Diffusion Pharmaceuticals Llc | Oral formulations of bipolar trans carotenoids |
US11491129B2 (en) | 2010-06-02 | 2022-11-08 | Diffusion Pharmaceuticals Llc | Oral formulations of bipolar trans carotenoids |
CN103917549A (en) * | 2011-11-09 | 2014-07-09 | 巴斯夫欧洲公司 | Method for producing oxo-vinyl-ionol and O-protected derivatives thereof |
TWI576333B (en) * | 2011-11-09 | 2017-04-01 | 巴地斯顏料化工廠 | Process for the preparation of oxovinylionol and its o-protected derivatives |
US9061982B2 (en) | 2011-11-09 | 2015-06-23 | Basf Se | Process for the preparation of oxovinylionol and its O-protected derivatives |
EP2776447B1 (en) | 2011-11-09 | 2018-05-30 | Basf Se | Method for producing oxo-vinyl-ionol and o-protected derivatives thereof |
WO2013068465A3 (en) * | 2011-11-09 | 2013-07-18 | Basf Se | Method for producing oxo-vinyl-ionol and o-protected derivatives thereof |
WO2013068465A2 (en) | 2011-11-09 | 2013-05-16 | Basf Se | Method for producing oxo-vinyl-ionol and o-protected derivatives thereof |
US9758500B2 (en) | 2012-04-16 | 2017-09-12 | Basf Se | Process for the preparation of (3E, 7E)-homofarnesol |
CN103245658A (en) * | 2013-04-23 | 2013-08-14 | 山西省食品质量安全监督检验研究院 | Fast detection method of bromate in bread |
CN103245658B (en) * | 2013-04-23 | 2015-07-29 | 山西省食品质量安全监督检验研究院 | The method for quick of bromate in a kind of bread |
CN105705039A (en) * | 2013-11-07 | 2016-06-22 | 帝斯曼知识产权资产管理有限公司 | Process for the purification of astaxanthin |
EP3514143A1 (en) * | 2013-11-07 | 2019-07-24 | DSM IP Assets B.V. | Dietary supplements, oily suspensions and powdery formulations comprising synthetic food-grade astaxanthin |
WO2015067706A1 (en) * | 2013-11-07 | 2015-05-14 | Dsm Ip Assets B.V. | Process for the purification of astaxanthin |
CN105705040A (en) * | 2013-11-07 | 2016-06-22 | 帝斯曼知识产权资产管理有限公司 | Process for the purification of astaxanthin |
CN105705042A (en) * | 2013-11-07 | 2016-06-22 | 帝斯曼知识产权资产管理有限公司 | Process for the purification of astaxanthin |
WO2015067707A1 (en) * | 2013-11-07 | 2015-05-14 | Dsm Ip Assets B.V. | Process for the purification of astaxanthin |
WO2015067711A1 (en) * | 2013-11-07 | 2015-05-14 | Dsm Ip Assets B.V. | Process for the purification of astaxanthin |
WO2015067705A1 (en) * | 2013-11-07 | 2015-05-14 | Dsm Ip Assets B.V. | Process for the purification of astaxanthin |
CN109965279A (en) * | 2013-11-07 | 2019-07-05 | 帝斯曼知识产权资产管理有限公司 | The powderous preparations of food-grade astaxanthin comprising synthesis, oily suspended matter and dietary supplements |
CN105705041A (en) * | 2013-11-07 | 2016-06-22 | 帝斯曼知识产权资产管理有限公司 | Process for the purification of astaxanthin |
WO2015067703A1 (en) * | 2013-11-07 | 2015-05-14 | Dsm Ip Assets B.V. | Process for the purification of astaxanthin |
US11185523B2 (en) | 2016-03-24 | 2021-11-30 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer |
CN107739390A (en) * | 2017-09-29 | 2018-02-27 | 上虞新和成生物化工有限公司 | A kind of synthetic method of astaxanthin intermediate |
CN109503545A (en) * | 2018-11-30 | 2019-03-22 | 彩客化学(沧州)有限公司 | A kind of preparation method of 1,4- cyclohexanedione monoethylene acetal |
CN111302925A (en) * | 2020-03-16 | 2020-06-19 | 万华化学集团股份有限公司 | Method for preparing cyclic α -unsaturated ketone |
CN111302925B (en) * | 2020-03-16 | 2023-05-30 | 万华化学集团股份有限公司 | Method for preparing cyclic alpha, beta-unsaturated ketone |
CN112409155A (en) * | 2020-10-28 | 2021-02-26 | 肇庆巨元生化有限公司 | Preparation method of 4-oxo-beta-ionone |
CN114940644A (en) * | 2022-06-20 | 2022-08-26 | 万华化学集团股份有限公司 | Crystallization method of 2, 7-dimethyl-2, 4, 6-octatriene-1, 8-dialdehyde |
CN114940644B (en) * | 2022-06-20 | 2024-04-09 | 万华化学集团股份有限公司 | Crystallization method of 2, 7-dimethyl-2, 4, 6-octatriene-1, 8-dialdehyde |
Also Published As
Publication number | Publication date |
---|---|
WO2007072529A3 (en) | 2007-11-22 |
AR058750A1 (en) | 2008-02-20 |
ITMI20052486A1 (en) | 2007-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007072529A2 (en) | Process for the synthesis of intermediates for the preparation of astaxanthin | |
CN107417505B (en) | Preparation method of alpha-halogenated tetramethyl cyclohexanone and (2,3,4, 4-tetramethylcyclopentyl) methyl carboxylic ester | |
EP1853548A1 (en) | Process for the preparation of benzoic acid derivatives via a new intermediate of synthesis | |
HU204044B (en) | Process for producing trans-aryltetraloncarboxylic acid derivatives | |
Hanamoto et al. | Synthesis and reactions of α-fluorovinylphosphonium salts | |
EP3505506B1 (en) | Method for producing 3,7-dimethyl-7-octenol and method for producing 3,7-dimethyl-7-octenyl carboxylate compound | |
EP1669353B1 (en) | Process for preparing alpha, beta - unsaturated esters | |
EP1262476B1 (en) | Processes for preparing quinoline derivatives and intermediates thereof | |
JP5186115B2 (en) | 2-Substituted benzyl-3,3-difluoroacrylic acid ester derivatives and process for producing them | |
JP2003335735A (en) | Method for producing perfluoroisopropylanilines | |
US5449844A (en) | Intermediates for preparing vitamins A and E and carotenoids | |
Piemontese et al. | Convenient synthesis of some 3-phenyl-1-benzofuran-2-carboxylic acid derivatives as new potential inhibitors of CLC-Kb channels | |
JP7216043B2 (en) | Process for producing 6-isopropenyl-3-methyl-9-decenyl acetate and intermediates thereof | |
Chambers et al. | An improved synthesis of 5-fluorothiophene-2-carboxylic acid | |
CN110483534B (en) | Preparation method of (2,4,5, 7-tetrahydropyrano [3,4-c ] pyrazol-7-yl) methanol | |
EP1375467B1 (en) | 2-Bromomethyl-6-methyl-benzoic acid and a process for the preparation thereof | |
EP0454871B1 (en) | Alpha, beta-unsaturated ketone and ketoxime derivative | |
KR100835604B1 (en) | Method for preparing unsaturated ketone and their derivatives for anticancer effect | |
RU2277083C1 (en) | Method for preparing 5,8-dihydroxy-2,6,7-trimethoxy-3-ethyl-1,4-naphthoquinone | |
WO2023082149A1 (en) | Process and intermediates for preparation of isofetamid | |
JP4800933B2 (en) | Process for producing cyclopropane monoacetal derivative and its intermediate | |
KR100699928B1 (en) | Process for preparing the intermediate compounds for ppar ? ligands | |
JP2581186B2 (en) | Method for producing 4-substituted-2-cyclopentenone ester derivative | |
KR20190022894A (en) | Preparation of 3- (trifluoromethyl) pyrazine-2-carboxylic acid ester | |
KR100570279B1 (en) | Intermediates of coenzyme qn and process for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06832350 Country of ref document: EP Kind code of ref document: A2 |